Two Effective Options, Two Different Risk Profiles
Placeholder: both hormone therapies work well but harm differently.
- 5–10 yrs: Treatment duration (placeholder text)
- 2: Therapy class count (SERM vs AI)
- ~70%: ER+ cancers (placeholder text)
- Multiple: Decision drivers (placeholder text)
Why the choice matters
Placeholder: efficacy is similar, side effects diverge over years of use.
Partial Agonism Drives Uterine and Clotting Risk
Placeholder: tamoxifen acts as estrogen agonist in the uterus and clotting cascade.
- ~2–3×: Endometrial cancer RR (placeholder text)
- ~2×: VTE risk increase (placeholder text)
- SERM: Mechanism (partial agonist)
- Years 2–5: Peak risk window (placeholder text)
Endometrial effect
Placeholder: agonist action thickens uterine lining over time.
Clotting factor effect
Placeholder: estrogen-like effect on clotting factors raises thromboembolism risk.
Placeholder: clot and endometrial risk rise steadily with years on drug.
Estrogen Suppression Drives Bone and Joint Risk
Placeholder: AIs suppress estrogen almost completely, unlike tamoxifen.
- ~2–3%: Bone density loss/yr (placeholder text)
- ~50%: Arthralgia incidence (placeholder text)
- Aromatase block: Mechanism (near-total suppression)
- Elevated: Fracture risk (placeholder text)
Bone density effect
Placeholder: estrogen loss accelerates osteoclast activity and bone loss.
Joint pain effect
Placeholder: arthralgia and stiffness are common, dose-duration linked.
Placeholder: bone and joint risk climb steadily across the therapy years.
Matching the Drug to the Patient
Placeholder: individual history shifts which side-effect profile is safer.
- Favors AI: Clot history (placeholder text)
- Favors AI: Endometrial concern (placeholder text)
- Favors SERM: Osteoporosis risk (placeholder text)
- Favors SERM: Joint disease (placeholder text)
Weighing personal history
Placeholder: prior clots or uterine issues steer away from tamoxifen.
Bone and joint considerations
Placeholder: pre-existing bone or joint disease steers away from AI.
A Personalized, Sometimes Sequential, Choice
Placeholder: menopausal status and risk factors together guide final selection.
- Common: Sequential switching (placeholder text)
- Key input: Menopausal status (placeholder text)
- Recommended: Shared decision (placeholder text)
- 5–10 yrs: Course length (placeholder text)
Putting it together
Placeholder: profile, status, and history combine into one plan.
Placeholder: many patients switch drugs mid-course to balance risks.